SELLAS Life Sciences Group, Inc.

Stocks

Market Closed - Nasdaq 16:00:00 2026-10-28 EDT			After hours 19:17:18
10.38 ^USD	-14.71%		10.24	-1.35%

09-25	SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer	CI
09-14	Top Premarket Decliners	MT

Published on 10/29/2025 at 05:20 pm EDT - Modified on 10/29/2025 at 06:21 pm EDT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good morning, and welcome to the SELLAS Life Sciences R&D Day. As a reminder, this call is being recorded, and a replay will be made available on the

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

09-25	SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer	CI
09-14	Top Premarket Decliners	MT
08-31	Social Buzz: Wallstreetbets Stocks Mixed Premarket Monday; SELLAS Life Sciences to Advance, Tesla to Decline	MT
08-24	Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Monday; Sellas to Rise, Applied Optoelectronics to Fall	MT
08-11	Sellas Life Sciences Q2 Loss Narrows	MT
08-11	Earnings Flash (SLS) SELLAS Life Sciences Posts Q2 Loss $0.05, vs. FactSet Est of $0.05 Loss	MT
08-11	SELLAS Life Sciences Group, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-29	Social Buzz: Wallstreetbets Stocks Advance Premarket Monday; SELLAS Life Sciences, Strategy to Open Higher	MT
05-12	SELLAS Life Sciences Group Q1 Loss Narrows	MT
05-12	Earnings Flash (SLS) SELLAS Life Sciences Posts Q1 Loss $0.05, vs. FactSet Est of $0.06 Loss	MT
05-12	SELLAS Life Sciences Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-22	SELLAS Life Sciences Group, Inc.(NasdaqCM:SLS) added to S&P Biotechnology Select Industry Index	CI
03-19	SELLAS Life Sciences Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-17	Sellas Life Sciences Group Announces Preclinical Data On SLS009 In AML	CI
03-12	Sellas Says First Patient Enrolled in Phase 2 Trial of SLS009 in Acute Myeloid Leukemia	MT